Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) | MicrobiomeTrials← Back to trialsNCT01343355
Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
TERMINATEDPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2011-01Est. Completion: 2011-10
Enrollment target: 15 participants Locations- Iseikai Medical Corporation, Shoyo Kashiwadai Hospital, Kanagawa, Japan
Other microbiome trials you might be interested in
HTLV-I InfectionTropical Spastic Paraparesis
Objective:
Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare n…
Bethesda, United States
HAM/TSP
Background:
HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare, progressive disease. It occu…
Bethesda, United StatesEst. completion Dec 31, 2027
Recruiting
Spinal Cord InjuryNeurological ConditionsRehabilitation Exercise
This is a randomised, blinded and controlled Phase I trial to measure the safety, feasibility and efficacy of a combined…
Multiple LocationsEst. completion May 1, 2031